Discussions

In the past few decades, Creative Biolabs has been designed to address the multiple challenges caused by TAC-T cells, providing well-mature, comprehensive solutions for TAC modification and safety assessment. As a result, solving the key issues in the field of TAC-TT cell therapy has a unique advantage, most notably through the discovery and development of high efficiency and specificity in TAC gene delivery technologies.

In our company, the production of TAC-T cells has been done through viral vectors, including but not limited to retroviruses, lentiviruses, herpes simplex viruses, murine Stem Cell Viruses (MSCV), adenoviruses, and adeno-associated viruses. The studies conducted by our labs have shown that these vectors can provide low pathogenicity, genetic safety, and efficient transduction for TAC-based virus packaging. Therefore, it has been considered a typical vector type for TAC gene delivery.

In recent years, Creative Biolabs democratizes cellular therapy for cancer treatment by adopting a non-viral vector manufacturing process that reduces the cost of treatment while improving the safety of cellular therapy. Creative Biolabs exclusively licenses a strong set of non-viral vector patents for the production of engineered TAC-T cells for oncology.